- Previous Close
2.8600 - Open
2.8600 - Bid --
- Ask --
- Day's Range
2.7700 - 2.9490 - 52 Week Range
2.4900 - 8.8700 - Volume
40,362 - Avg. Volume
58,398 - Market Cap (intraday)
109.191M - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6600 - Earnings Date Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.86
Orchestra BioMed Holdings, Inc. operates as a biomedical company. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. The company's products also comprise FreeHold devices and additional minimally invasive surgery enabling devices. The company has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
orchestrabiomed.comRecent News: OBIO
View MorePerformance Overview: OBIO
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OBIO
View MoreValuation Measures
Market Cap
109.19M
Enterprise Value
58.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
39.78
Price/Book (mrq)
3.31
Enterprise Value/Revenue
22.33
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.90%
Return on Equity (ttm)
-120.84%
Revenue (ttm)
2.64M
Net Income Avi to Common (ttm)
-61.02M
Diluted EPS (ttm)
-1.6600
Balance Sheet and Cash Flow
Total Cash (mrq)
66.81M
Total Debt/Equity (mrq)
50.15%
Levered Free Cash Flow (ttm)
-25.45M